]>
IRCT2016100918946N4 IRCT 2016-11-30 Vice chancellor for research, Tabriz University of Medical Sciences Effects of atorvastatin on diabetic nephropathy Effects of atorvastatin on proteinuria of type 2 diabetic nephropathy in patients with history of gestational diabetes mellitus 2014-10-01 anticipated 42 Complete https://irct.ir/trial/17061 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 2-3 Diabetic nephropathy. Intervention 1: Intervention group: Atorvastatin 10 mg per day will be administered to the patients in intervention group for 90 days. At the end of the third month, patients will be asked not to use Atorvastatin for a month. Intervention 2: Control group: Daily Placebo will be administered to the patients in control group for 90 days. At the end of the third month, patients will be asked not to use placebo for a month.
public Dr.Parviz Saleh
Emam Reza educational-medical centre, Azadi street, Golgasht Avenue
Tabriz Iran (Islamic Republic of) +98 41 3334 1317 p.zzss@yahoo.com Emam Reza educational-medical center scientific Dr. Parviz Saleh
Emam Reza educational-medical centre, Azadi street, Golgasht Avenue
Tabriz Iran (Islamic Republic of) +98 41 3334 1317 p.zzss@yahoo.com Emam Reza educational-medical center Iran (Islamic Republic of) Inclusion criteria: Patients between 20 to 65 years old; patients with type 2 diabetes mellitus; history of gestational diabetes mellitus; proteinuria levels lower than 3 g/d (nephrotic range); estimated glomerular filtration rate more than 30 mL/min/1.73m2 Exclusion criteria: use of fibrates, statins antagonists, aspirin, allopurinol, β-blockers, pentoxifylline, fish oil, other antioxidant drugs consumption in past 6 months; active smoking; active coronary artery disease in the previous 6 months; diabetic foot; hepatitis; poorly controlled diabetes (Hb-A1c more than 7.5%) 20 years 65 years Female E10.2 Insulin-dependent diabetes mellitus with renal complications Treatment - Drugs Placebo Intervention group: Atorvastatin 10 mg per day will be administered to the patients in intervention group for 90 days. At the end of the third month, patients will be asked not to use Atorvastatin for a month. Control group: Daily Placebo will be administered to the patients in control group for 90 days. At the end of the third month, patients will be asked not to use placebo for a month. Lipid profile. Timepoint: Before intervention, 90 days after intervention initiation. Method of measurement: Blood samlple. Serum creatinine. Timepoint: Before intervention, 90 days after intervention initiation. Method of measurement: Blood samlple. Serum uric acid. Timepoint: Before intervention, 90 days after intervention initiation. Method of measurement: Blood samlple. Urine Protein. Timepoint: Before intervention, 90 days after intervention initiation. Method of measurement: Blood samlple. Vice chancellor for research, Tabriz University of Medical Sciences Approved 2014-09-23 Ethics committee of Tabriz University of Medical Sciences Tabriz university of medical sciences, Golgasht street, Azadi avenue. Tabriz Iran (Islamic Republic of)